Beyond Clinical Remission: Redefining Disease Control in Severe Asthma?
- PMID: 40736770
- PMCID: PMC12318803
- DOI: 10.4168/aair.2025.17.4.405
Beyond Clinical Remission: Redefining Disease Control in Severe Asthma?
Conflict of interest statement
YK has none to declare. WJS declares grants from Merck Sharp & Dohme Corp., Daewoong Pharmaceutical, and AstraZeneca, consulting fees from Merck, Bellus, AstraZeneca, Shionogi, and GSK, and lecture fees from Thermo Fischer/Immunotek, Celltrion, Daewoong Pharmaceutical, Organon, Merck, AstraZeneca, GSK, Sanofi, and Novartis.
References
-
- Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention, 2025. [place unknown]: GINA; 2025.
-
- Bidad N, Barnes N, Griffiths C, Horne R. Understanding patients’ perceptions of asthma control: a qualitative study. Eur Respir J. 2018;51:1701346. - PubMed
